Ophthalmic compositions containing loratadine
    37.
    发明授权
    Ophthalmic compositions containing loratadine 有权
    含有氯雷他定的眼用组合物

    公开(公告)号:US06635654B1

    公开(公告)日:2003-10-21

    申请号:US10340355

    申请日:2003-01-09

    IPC分类号: A61K3144

    CPC分类号: A61K9/0048 A61K31/4545

    摘要: The present invention is directed to an ophthalmic formulation which comprises a therapeutically effective amount of ethyl 4-(8-chloro-5,6-dihydro-11-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate, known as loratadine, a fatty acid ester, and a surfactant, which has been found to be useful in treating ocular allergies, especially allergic conjunctivitis, and related conditions.

    摘要翻译: 本发明涉及一种眼用制剂,其包含治疗有效量的4-(8-氯-5,6-二氢-11-苯并[5,6]环庚并[1,2-b]吡啶-11- 已经被发现可用于治疗眼部过敏症,特别是过敏性结膜炎和相关病症的已知的氯雷他定,脂肪酸酯和表面活性剂的亚胺基-1-哌啶羧酸酯。

    Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
    40.
    发明授权
    Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems 有权
    碳酸酐酶抑制剂持续释放眼内药物递送系统

    公开(公告)号:US08591885B2

    公开(公告)日:2013-11-26

    申请号:US11931769

    申请日:2007-10-31

    摘要: Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译: 生物相容性眼内药物递送系统包括碳酸酐酶抑制剂治疗剂和植入物,微粒,多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放,例如,当释放到患者的眼睛中时,治疗剂可以保持其三维结构,或者治疗剂可以具有改变的三种。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生,例如视网膜损伤,包括青光眼和增生性玻璃体视网膜病变等。